November 19, 2024

Wide Variation in SGLT2i Use Across U.S. Hospitals

Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.

Conexiant

November 19, 2024

Analysis Maps Broad Semaglutide Eligibility

An estimated 136.8 million U.S. adults are eligible for semaglutide, a number exceeding current eligibility for statins, according to an analysis.

Conexiant

November 14, 2024

Heat Waves Spike Atrial Fibrillation Risk

Reuters

November 14, 2024

Obesity-Linked Heart Disease Deaths Surge

Reuters

November 12, 2024

New Data Links GLP-1s to Poststroke Outcomes

Post-stroke patients taking GLP-1 or SGLT2 medications showed a 74% lower mortality risk and 84% lower heart attack risk over 3 years compared to untreated peers.

Conexiant

November 07, 2024

Artificial Livers to Grow on Space Station

Liver tissue experiments in space could lead to viable alternatives for transplantation, leveraging unique conditions in low Earth orbit. Source: [insert source here]

Reuters

November 04, 2024

Obesity Pill Safe in Early Trial, Drugmaker Reports

AstraZeneca's early-stage trial of an experimental weight-loss pill from Eccogene showed promise in safety and tolerability, paving the way for Phase II trials to reduce body weight in obese and overweight individuals.

Reuters

October 29, 2024

Early AKI Intervention Fails to Improve Outcomes

Despite achieving a 33.8% implementation rate of its recommendations versus 24.3% in usual care, a novel kidney action team intervention failed to improve outcomes in 4,003 hospitalized patients with acute kidney injury - highlighting the complex challenge of translating increased diagnostic testing into better clinical results.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant